We are excited to welcome our new members to our Medical Advisory Council. Welcome to: Julie Parsons, MD Nancy Kuntz, MD Perry Shieh, MD, PhD Randal Richardson, MD, MMS Elizabeth McNally, MD, PhD Anne Stratton, MD Oren Kupfer, MD Samuel Rosenfeld, MD Diane Murrell, LCSW Stacey Tarrant, BS, RD, LDN Terri Carry, MS, PT Our […]
Cure SMA Welcomes New Medical Advisory Council Committee Members Read More »
An important goal of our research funding strategy is to share scientific findings with the broader scientific community. Scientists who receive Cure SMA funding often publish their findings in peer-reviewed journals. This means that other scientists can learn from their results, which will pay dividends across the wider landscape of SMA research—allowing us to multiply
Cure SMA Funding Leads to 16 New Research Publications in 2014 Read More »
This year’s 4th Annual Hope on the Hill Congressional Dinner in Washington D.C. was a great success. Building on of this year’s Annual SMA Conference—also held in Washington D.C.—the Hope on the Hill Dinner brought together families, government, and industry leaders to work on shared goals like increasing awareness, advancing treatments for SMA, and improving
Hope on the Hill Advances Key SMA Legislative Priorities Read More »
Our strategic research approach includes four areas—basic research, drug discovery, clinical trials, and clinical care—working together toward our vision of a world without SMA. Cure SMA has invested $57 million in research since 1984, with $35 million in the past decade alone. In 2014, we provided funding to 26 different research projects across these four
Cure SMA Funds 26 Research Projects in 2014 Read More »
We are incredibly grateful to have received a large shipment of Kinetic Sand Activity Kits to be included in the Newly Diagnosed Type II Care Packages in honor of Jayce’s second birthday! Jayce’s parents, Jenna Gomez and Corey Clark, received a care package when they contacted Cure SMA after Jayce’s diagnosis. Since receiving the care
Kinetic Sand Donated for Care Packages Read More »
Isis recently announced that they have tested the first patient in CHERISH, a multi-center Phase 3 clinical study evaluating the efficacy and safety of the investigational compound, ISIS-SMNRx, in non-ambulatory children with spinal muscular atrophy (SMA). The study is a double-blind, randomized, sham-procedure controlled study in approximately 117 children with SMA at study centers in
Isis Expands Phase 3 Clinical Trials Read More »
This is an exciting time for the entire SMA community, as we celebrate another year of increasing momentum toward our goal of a treatment and cure for SMA. It’s also an exciting time for us at Cure SMA, as we’re looking forward to announcing over $1 million in new research grants in the next three
SMA Drug Pipeline Continues to Grow Read More »
The Society for Neuroscience (SfN) Meeting is the premiere neurobiology meeting, with over 30,000 scientists in attendance each year. This year’s meeting was held November 15-19 in Washington D.C. Two dozen presentations on spinal muscular atrophy were given at the meeting, several of which were by scientists funded by Cure SMA. Cure SMA-funded researchers Drs.
Cure SMA Researchers Present at Society for Neuroscience Meeting Read More »
PTC Therapeutics, Inc. announced today that its joint development program in Spinal Muscular Atrophy (SMA) with Roche and the SMA Foundation (SMAF) has started a Phase 1b/2a study in adult and pediatric patients. The placebo-controlled, randomized, multiple-dose study will enroll approximately 48 patients with SMA. Because of a mutation in the survival motor neuron gene
PTC Therapeutics Announces New Phase 1a/2b Clinical Trial Read More »
Isis recently announced the start of CHERISH, a multi-center Phase III clinical study evaluating the efficacy and safety of the investigational compound, ISIS-SMNRx, in non-ambulatory children with Spinal Muscular Atrophy (SMA). The study is a double-blind, randomized, sham-procedure controlled study in approximately 117 children with SMA at study centers in the US, Canada, Europe and
Isis Announces Second Phase III Clinical Trial Read More »
